The 37th Annual Transcatheter Cardiovascular Therapeutics (TCT2025) symposium was held grandly in San Francisco, USA, ...

M is positioned as the first oral antiviral sugar chemistry drug BOSTON, MASSACHUSETTS, Oct. 29, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology ...

The 37th Annual Transcatheter Cardiovascular Therapeutics (TCT2025) symposium was held grandly in San Francisco, USA, attracting widespread attention ...

Design Therapeutics, Inc. (($DSGN)) announced an update on their ongoing clinical study. Study Overview: Design Therapeutics, Inc. is conducting a ...

The Implantable Cell Therapy AVB-114 Demonstrated Favorable Safety and Effectiveness in the Phase II Trial for Crohn's Perianal Fistulas - NEWARK, Del., Oct. 29, 2025 /PRNewswire/ -- Avobis Bio LLC, a ...

M is positioned as the first oral antiviral sugar chemistry drug BOSTON, MASSACHUSETTS, Oct. 29, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC.

Results from the first randomized clinical trial in the United States to compare a sirolimus-eluting balloon (DEB) to control ...

Bristol-Myers Squibb Company (($BMY)) announced an update on their ongoing clinical study. Study Overview: Bristol-Myers ...

Phase 2 clinical trial underway with first patient dosed in October to support a clear path to Phase 3 based on previous ...

In a randomized crossover trial of 31 women with overweight, early and late time-restricted eating (TRE) produced no ...